Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BI 1361849 + Durvalumab + Tremelimumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BI 1361849||CV9202|BI1361849||BI 1361849 (CV9202) is a cancer vaccine comprising six mRNAs for non-small cell lung cancer-associated antigens, which may result in increased immune response against tumor cells (PMID: 25288198).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 136 PD-L1/PD-1 antibody 80||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|Tremelimumab||CP-675,206|Ticilimumab|CP-675206||CTLA4 Antibody 21 Immune Checkpoint Inhibitor 136||Tremelimumab (CP-675206) binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (PMID: 32620213, PMID: 32586937).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03164772||Phase Ib/II||BI 1361849 + Durvalumab + Tremelimumab||Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC||Completed||USA||0|